𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Engineered Synthetic Virus-Like Particles and Their Use in Vaccine Delivery

✍ Scribed by Dr. Arin Ghasparian; Tina Riedel; Jimy Koomullil; Dr. Kerstin Moehle; Dr. Christian Gorba; Dr. Dmitri I. Svergun; Dr. Adam W. Perriman; Prof. Stephen Mann; Dr. Marco Tamborrini ; Prof. Gerd Pluschke ; Prof. John A. Robinson

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
855 KB
Volume
12
Category
Article
ISSN
1439-4227

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Engineered nanoparticles have been designed based on the self‐assembling properties of synthetic coiled‐coil lipopeptide building blocks. The presence of an isoleucine zipper within the lipopeptide together with the aggregating effects of an N‐terminal lipid drives formation of 20–25 nm nanoparticles in solution. Biophysical studies support a model in which the lipid is buried in the centre of the nanoparticle, with 20–30 trimeric helical coiled‐coil bundles radiating out into solution. A promiscuous T‐helper epitope and a synthetic B‐cell epitope mimetic derived from the circumsporozoite protein of Plasmodium falciparum have been linked to each lipopeptide chain, with the result that 60–90 copies of each antigen are displayed over the surface of the nanoparticle. These nanoparticles elicit strong humoral immune responses in mice and rabbits, including antibodies able to cross‐react with the parasite, thereby, supporting the potential value of this delivery system in synthetic vaccine design.

📜 SIMILAR VOLUMES

Recombinant retrovirus-like particle for
Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development
✍ Delphine Desjardins; Christophe Huret; Charlotte Dalba; Florian Kreppel; Stefan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB

## Abstract ## Background The expression of Moloney murine leukemia virus (Mo‐MLV) gag proteins is sufficient to generate retrovirus‐like particles (retroVLPs) that can be used as antigen‐display platforms by pseudotyping with heterologous envelope proteins or by insertion of epitopes in structura

Enhanced mucosal and systemic immune res
Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems
✍ Jeong-Sook Park; Yu-Kyoung Oh; Min-Jeong Kang; Chong-Kook Kim 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB

## Abstract To develop more potent and convenient mucosal human papillomavirus (HPV) vaccines, we tested the effect of thermosensitive mucoadhesive vaginal vaccine delivery systems on the local and systemic antibody responses to HPV 16 L1 virus‐like particles (VLP). HPV 16 L1 VLP expressed from rec

Expression and antigenicity of virus-lik
Expression and antigenicity of virus-like particles of norovirus and their application for detection of noroviruses in stool samples
✍ Kunio Kamata; Kuniko Shinozaki; Mineyuki Okada; Yoshiyuki Seto; Shinichi Kobayas 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

Human noroviruses (NoVs), members of the genus Norovirus in the family Caliciviridae, are the leading agents of nonbacterial acute gastroenteritis worldwide. Human NoVs are currently divided into at least two genogroups, genogroup I (GI) and genogroup II (GII), each of which contains at least 14 and

Safety, immunogenicity, and efficacy of
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women
✍ Gonzalo Perez; Eduardo Lazcano-Ponce; Mauricio Hernandez-Avila; Patricia J. Garc 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naï